3 patents currently held
18 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Nov 2035. from the record
Of the 18 now held by other companies, 16 name Exact Sciences Corporation as their current owner, and 2 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Nov 2035
Next term end
3
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Dec 2037 · High confidence
Also notable
Ends Nov 2035 · High confidence
Also notable
Ends Jul 2042 · High confidence
Apparatuses, Methods, and Systems for Sample Collection and Dispersion
US 11,457,899
The most cited patent in this portfolio, cited by 5 later US patents, top 25% of utility patents granted in 2022 in our data. Protection runs to 2037.
Methods of Treating a Subject with a High Gleason Score Prostate Cancer
US 10,301,681
The earliest of the three still in force, granted 2019 and renewed since. Its term ends first, in 2035.
Methods for Developing Urine Biomarkers and for Detecting Bladder Cancer
US 12,378,608
Granted 2025. Too new for citation comparison; protection runs to 2042.
Formerly held, still cited
Notable
Ends Dec 2035 · High confidence
Cited by 20 later US patents, top 25% of utility patents granted in 2019 in our data. Protection runs to 2035.
now held by Exact Sciences Corporation
Also notable
Ends May 2032 · Medium confidence
Cited by 4 later US patents, top 25% of utility patents granted in 2022 in our data. Protection runs to 2032.
now held by Exact Sciences Corporation
Also notable
Ends Jun 2033 · Medium confidence
A family of 5 related applications built on the 2021 grant. Protection runs to 2033.
now held by Exact Sciences Corporation
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 28, 2026The maintenance fee for Methods of Treating a Subject with a High Gleason Score Prostate Cancer (US 10,301,681) comes due Nov 28, 2026. Unpaid by May 28, 2027, it lapses early.
Recent changes
- Oct 12Assignment recorded on 1 record: Skog, Johan Karl Olov and 1 other to Exosome Diagnostics, Inc. Recorded Oct 12, 2026, executed Oct 28, 2018. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76653, frame 631.
- 1 of the patents on this record was granted since Aug 16, 2026
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| Methods for Developing Urine Biomarkers and for Detecting Bladder Cancer | 1 in force | to Jul 2042 |
| Apparatuses, Methods, and Systems for Sample Collection and Dispersion | 1 in force | to Dec 2037 |
| Methods of Treating a Subject with a High Gleason Score Prostate Cancer | 1 in force | to Nov 2035 |
Patents held now
Soonest term end first.
Showing 1 to 3 of 3
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,301,681 | Methods of Treating a Subject with a High Gleason Score Prostate Cancer In force · High confidence | In force | High confidence | |
| US 11,457,899 | Apparatuses, Methods, and Systems for Sample Collection and Dispersion In force · High confidence | In force | High confidence | |
| US 12,378,608 | Methods for Developing Urine Biomarkers and for Detecting Bladder Cancer In force · High confidence | In force | High confidence |
Also on record, not counted in the 3: 18 patents in force now held by others · 7 applications pending · 16 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.